U.S. regulators Monday approved Bristol-Myers Squibb Co.’s Opdivo for advanced skin cancer, the latest drug to reach the market in the emerging field of cancer immunotherapy.. The decision by the Food and Drug Administration means Bristol-Myers now has two drugs on the market that work by unleashing the body’s immune system to attack tumors, helping to solidify the company’s lead in an area of cancer treatment that has drawn wide interest across the pharmaceutical industry.